H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Akebia Therapeutics (NASDAQ: AKBA) after Akebia announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE